35th week of 2008 patent applcation highlights part 44 |
Patent application number | Title | Published |
20080206116 | FRICTION STIR WELDING METHOD FOR LAMINATED MEMBER AND HYDROGEN REACTOR - The present invention is relates to a method for alternately laminating each first metal sheet and each second metal sheet in three or more layers, wherein a melting point of the second metal sheet is higher than that of the first metal sheet, and welding them together by friction stir welding. | 2008-08-28 |
20080206117 | METHOD AND APPARATUS FOR REFORMING FUEL - A gas mixture containing a fuel, water and air is supplied to one end of a reforming room, and a reformed gas containing hydrogen is discharged from the other end thereof. Two or more such reforming units are connected in series, and the upstream part of each reforming room is filled with a first catalyst which catalyzes a partial oxidation reaction in an oxygen-rich environment, and the downstream part is filled with a second catalyst which performs the reforming reaction. The gas mixture which has been heated in a heating unit passes through a distribution tube and is distributed evenly to the reforming units. The reforming room is composed of a reforming tube in which a reforming catalyst is charged, or two or more such reforming tubes, parallel to each other. After being reformed the high-temperature reformed gas is passed around the reforming tubes, and fed back to a manifold. | 2008-08-28 |
20080206118 | Steriliser - A sterilizer comprising a sterilization chamber ( | 2008-08-28 |
20080206119 | Jacket of a Steam Sterilizer Chamber - A jacket of a steam sterilizer embedding a sterilization chamber ( | 2008-08-28 |
20080206120 | Method For Purifying Waste Gases of a Glass Melting Process, Particularly For Glasses For Lcd Display - The invention relates to a method for purifying waste gases of a glass melting process during which SiO | 2008-08-28 |
20080206121 | Solid solution wide bandgap semiconductor materials - A substrate and method for growing a semi-conductive crystal on an alloy film such as (AIN) | 2008-08-28 |
20080206122 | Manufacture of silica aerogel via vapor phase reaction - A kinetically controlled vapor reaction process for synthesizing silica areogel in a reaction container by injection of a precursor reagent vapor, a catalyst reagent vapor, super saturated steam as a component of the catalyst solution, and a hydrophobic reagent vapor amd continuously mixing vapor droplets of the precursor, catalyst and water reagents in a super saturated state to continuously nucleate in a hydrolysis/poly-condensation reaction and deposit as silica aerogel. | 2008-08-28 |
20080206123 | SILICON FEEDSTOCK FOR SOLAR CELLS - The present invention relates to silicon feedstock for producing directionally solidified silicon ingots, thin sheets and ribbons for the production of silicon wafers for PV solar cells where the silicon feedstock contains between 0.2 and 10 ppma boron and between 0.1 and 10 ppma phosphorus distributed in the material. The invention further relates to directionally solidified silicon ingot or thin silicon sheet or ribbon for making wafers for solar cells containing between 0.2 ppma and 10 ppma boron and between 0.1 ppma and 10 ppma phosphorus distributed in the ingot, said silicon ingot having a type change from p-type to n-type or from n-type to p-type at a position between 40 and 99% of the ingot height or sheet of ribbon thickness and having a resistivity profile described by an exponential curve having a starting value between 0.4 and 10 ohm cm and where the resistivity value increases towards the type change point. Finally the invention relates to a method for producing silicon feedstock for producing directionally solidified silicon ingots, thin sheets and ribbons for the production of silicon wafers for PV solar cells. | 2008-08-28 |
20080206124 | Method of producing nano-scaled graphene and inorganic platelets and their nanocomposites - Disclosed is a method of exfoliating a layered material (e.g., graphite and graphite oxide) to produce nano-scaled platelets having a thickness smaller than 100 nm, typically smaller than 10 nm, and often between 0.34 nm and 1.02 nm. The method comprises: (a) subjecting the layered material in a powder form to a halogen vapor at a first temperature above the melting point or sublimation point of the halogen at a sufficient vapor pressure and for a duration of time sufficient to cause the halogen molecules to penetrate an interlayer space of the layered material, forming a stable halogen-intercalated compound; and (b) heating the halogen-intercalated compound at a second temperature above the boiling point of the halogen, allowing halogen atoms or molecules residing in the interlayer space to exfoliate the layered material to produce the platelets. Alternatively, rather than heating, step (a) is followed by a step of dispersing the halogen-intercalated compound in a liquid medium which is subjected to ultrasonication for exfoliating the halogen-intercalated compound to produce the platelets, which are dispersed in the liquid medium. The halogen can be readily captured and re-used, thereby significantly reducing the impact of halogen to the environment. The method can further include a step of dispersing the platelets in a polymer or monomer solution or suspension as a precursor step to nanocomposite fabrication. | 2008-08-28 |
20080206125 | Catalyst System for a Multi-Walled Carbon Nanotube Production Process - The present invention relates to a catalyst system for the selective conversion of hydrocarbons into multi-walled carbon nanotubes and hydrogen comprising a compound of the formula: (Ni,Co)Fe | 2008-08-28 |
20080206126 | Higher than 30% concentration lime slurries, preparation and uses thereof - The present invention relates to a composition comprising water, more than 30% w/w of calcium hydroxide, and >0.2% w/w dispersant. A process for preparing such a composition is also disclosed. The composition which can be in the form of a 45-55% concentration lime slurry is particularly useful for converting concentrated ammonium lignosulfonate into calcium lignosulfonate, for converting ammonium lignosulfonate into low sulfate calcium, potassium, sodium, or magnesium lignosulfonate and mixtures thereof, for removing soluble sulfate from concentrated sodium, potassium, ammonium or magnesium lignosulfonate or for treating a weak liquor obtained from the pulp and paper industry. | 2008-08-28 |
20080206127 | Iron Oxide Precipitaion from Acidic Iron Salt Solutions - Improved methods for treating metallurgical compositions involve reacting a metallurgical composition with an aqueous nitric acid solution. The reaction is performed at a pressure or at least about 220 psig and at a temperature of at least 100° C. The metallurgical composition comprises iron and one or more non-ferrous metals. The reaction dissolves at least a portion of the non-ferrous metal compositions into the solution which is in contact with solid ferric oxide. The reaction can be repeated on the isolated solids to increase the purity of ferric oxide in the solids. Zinc can be removed from mixed metal solutions obtained from furnace dust by adding base to precipitate zinc hydroxide. | 2008-08-28 |
20080206128 | Process for recycling industrial waste magnesium oxide/magnesium hydroxide for use in magnesium oxide based cement/concrete and method of preparation - The inventor's discovery of recyclable Industrial Waste Magnesium Oxide/Magnesium Hydroxide materials, which are currently available from numerous magnesium based industrial processes/sources, as well as the identification of various state-of-the-art, contemporary and/or advanced materials dehydration and separation technologies, is intended to advance the cost-effective, eco-friendly, superior quality usefulness of Magnesium Oxide based cement concrete. | 2008-08-28 |
20080206129 | Methods for transforming compounds using a metal alloy and related apparatus - A compound, such as an organic compound, can be transformed utilizing a melted metal alloy by generating an energy gradient in a system that includes the compound and the alloy. Accordingly, provided are methods for transforming compounds and related apparatuses. | 2008-08-28 |
20080206130 | IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES - A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor. | 2008-08-28 |
20080206131 | Compositions and Method for Multimodal Imaging - Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal. | 2008-08-28 |
20080206132 | Cancerous Disease Modifying Antibodies - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-08-28 |
20080206133 | Cancerous Disease Modifying Antibodies - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-08-28 |
20080206134 | Radio-opaque hemostatic agents and devices and methods for the delivery thereof - A radiographic composition for promoting the formation of clots in blood includes a zeolite and iodine. A device for promoting the clotting of blood at an internal wound site includes a catheter; a delivery instrument insertable through the catheter; a radioopaque blood clotting agent that deliverable through the delivery instrument; and a positive pressure apparatus that can dispense the blood clotting agent to the wound site through the delivery instrument. A system for radiographically imaging an internally bleeding wound includes means for delivering a radioopaque blood clotting agent and means for radiographically imaging the radioopaque blood clotting agent. A method of imaging an internally bleeding wound includes the steps of inserting a catheter into a patient; advancing the catheter to a point adjacent the bleeding wound; depositing a radioopaque zeolite at the bleeding wound; and imaging the radioopaque zeolite to monitor blood-clotting caused by the zeolite. | 2008-08-28 |
20080206135 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid - The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest. | 2008-08-28 |
20080206136 | Binding Peptidomimetics and Uses of the Same - A multimeric peptidomimetic that comprises two or more monomers is disclosed. The monomers comprise an exocyclic peptide comprising a ring structure, a flexible linker sequence and a multimeric motif. Use of the monomers, a nucleic acid molecule encoding monomers, recombinant expression vectors comprising the nucleic acid molecule and host cells comprising a recombinant expression vector are disclosed. Methods of delivering a drug, a toxin, a nucleic acid molecule, a radionuclide or a detectable compound to a cell are disclosed. | 2008-08-28 |
20080206137 | 11C-Labeled Benzyl-Lactam Compounds and Their Use as Imaging Agents - The invention relates to “C-labeled compounds, their preparation, compositions comprising an effective amount of a “C-labeled compound, and the use of a “C-labeled compound as a radiopharmaceutical for positron emission tomography. | 2008-08-28 |
20080206138 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - Compounds derived from phenylethyl imidazole carboxylic acid esters have shown selective accumulation of radioactivity in the adrenal cortex, when labeled with a radioactive halogen. In particular, these compounds bind selectively to adrenocortical tissue facilitating the diagnosis of adrenal cortical masses such as incidentaloma, adenoma, primary and metastatic cortical carcinoma. Trace amounts are injected intravenously and accumulate rapidly in the adrenals, maintaining a high radioactivity plateau, which permits external imaging using computed SPECT (single photon emission) or PET (positron emission) techniques. | 2008-08-28 |
20080206139 | DELIVERY SYSTEM FOR DIAGNOSTIC AND THERAPEUTIC AGENTS - Nanovesicles are specifically targeted to abnormal cells. The targeting moiety is conjugated to the nanovesicle which comprises a therapeutic composition. These nanovesicles are useful in treatment of a wide spectrum of disorders. | 2008-08-28 |
20080206140 | Cspcna Isoform Antibodies and Uses Thereof - Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed. | 2008-08-28 |
20080206141 | Optical Imaging Contrast Agents - The invention relates to optical imaging contrast agents. More specifically the invention relates to optical imaging activatable contrast agent for use in diagnosis and for monitoring the effect of treatment. The contrast agent employs a combined targeting and activation approach and comprises a target binding ligand (V), an enzyme cleavable group (E), a fluorophore (D) and a quencher agent (Q) covalently linked in one molecule. | 2008-08-28 |
20080206142 | Novel Peptides That Promote Lipid Efflux - Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention. | 2008-08-28 |
20080206143 | Blockade of Elr+Cxc Chemokines as a Treatment For Inflammatory and Autoimmune Disease - Experimental autoimmune encephalomyelitis (EAE) is a ThI-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). Herein it is demonstrated that CXCR2, a chemokine receptor involved in the recruitment of neutrophils, is expressed in tissues with EAE lesions. Blockade or deficiency of CXCR2 reduces the infiltration of neutrophils to sites of inflammation. Thus provided herein are reagents that antagonize or inhibit ELR+CXC chemokines and methods of use of these reagents in preventing and treating organ-specific autoimmune diseases like multiple sclerosis, and methods or treating various inflammatory conditions and diseases. | 2008-08-28 |
20080206144 | MDR1 VARIANTS AND METHODS FOR THEIR USE - This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation. | 2008-08-28 |
20080206145 | Gastro-Retentive Diagnostic Assemblies - The present invention provides a gastro-retentive diagnostic assembly (GRDA) for use in determining a condition of a subject's gastrointestinal tract (GI tract), comprising a folded single or multi-layered device comprising a diagnostic utility, such as a contrasting agent, the device prior to folding being essentially planar, and included in a delivery system for oral intake, the delivery system being adapted to release the device once in the stomach, whereupon release said device unfolds into an unfolded shape that results in the retention of the device in the stomach. Further provided are methods of determining a condition of a subject's GI tract by the use of the GRDA of the invention, as well as uses of a single or multi-layered device comprising a diagnostic utility when in a folded or unfolded shape, and method of preparing the GRDA of the invention. | 2008-08-28 |
20080206146 | Functionalized Magnetic Nanoparticles and Methods of Use Thereof - The present invention provides functionalized magnetic nanoparticles comprising a functional group, which functionalized magnetic nanoparticles exhibit differential binding to a tissue, indulging brain tissue, bone, and vascular tissues. The present invention further provides compositions, including pharmaceutical compostions, comprising a subject functionalized magnetic nanoparticle. The present invention further provides diagnostic and research methods including use of subject functionized magnetic nanoparticles. The present invention further provides a magnetic resonance imaging (MRI)-visible drug delivery system; drugs using MRI, as well as tissue-specific drug delivery. | 2008-08-28 |
20080206147 | Method for the Use of [11C]Carbon Monoxide in Labeling Synthesis of 11C-Labelled Acids by Photo-Induced Free Radical Carbonylation Under Mild Conditions Using Sulfoxides - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with sulfoxides and triethylamine are provided. The resultant carbon-isotope labeled acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided. | 2008-08-28 |
20080206148 | Method for radiographic targeting of malignant tumors and apparatus for focusing rays - A method and apparatus for immunoimaging and destruction of malignant tumors using immunoimaging agents comprising nanoclusters incorporating monoclonal antibodies that selectively bind to the cell membrane of tumor cells, and conjugated payloads comprising an encapsulated near-infrared (NIR) fluorescing crystal. The encapsulated fluorescing crystal compound provides excellent non-radiometric imaging of the tumor, and the non-antigenic metal coating encapsulating the fluorescing crystal particles provides a non-destructive necrotic killing of the tumor cells by low-level radiometric amplification and heating of the tumor cell membrane. Thus the very same nanoclusters used during imaging also serve to kill the tumor cells by necrosis, damaging the cell membrane by overheating as a result of secondary irradiation (not by harmful radiometric-induced apoptosis). Also included is a radiometric treatment platform for that better focuses the marked tumor by articulating the patient (180 degrees along one axis, 90 degrees along another), thereby minimizing incident radiation and destroying the tumor without exposing healthy tissue. | 2008-08-28 |
20080206149 | METHOD, DYE AND MEDICAMENT FOR STAINING THE INTERNAL LIMITING MEMBRANE, EPIRETINAL MEMBRANE, THE VITREOUS AND/OR THE CAPSULE OF AN EYE - The present invention concerns a method of staining the internal limiting membrane, the vitreous and/or the lens capsule of the eye as well as dyes and medicaments suitable for this method. Such dyes, medicaments and methods are needed in ophthalmic surgery, in particular in macular and/or cataract surgery and/or vitrectomy. | 2008-08-28 |
20080206150 | Nanoparticles for Imaging Atherosclerotic Plaque - Atherosclerosis is an inflammatory disease of the arterial walls and represents a significant health problem in developed nations. Described is a targeted Magnetic Resonance Imaging (MRI) contrast agent for in vivo imaging of early stage atherosclerosis. Early plaque development is characterized by the influx of macrophages, which express a class of surface receptors known collectively as the scavenger receptors (SR). The macrophage scavenger receptor class A (SRA) is highly expressed during early atherosclerosis. The macrophage SRA therefore presents itself as an ideal target for labeling of lesion formation. By coupling a known ligand for the scavenger receptor, dextran sulfate, to a MRI contrast agent, early plaque formation can be detected in vivo. Targeted MR contrast agents offer a unique opportunity to visualize early plaque development in vivo with high sensitivity and resolution, allowing or early diagnosis and treatment of atherosclerosis. | 2008-08-28 |
20080206151 | Liposomes - The present invention relates to a process for the manufacture of targeting liposomes comprising vector compounds conjugated to the hydrophilic part of modified phospholipids. The present invention provides the modified phospholipids and liposomes containing said modified phospholipids. | 2008-08-28 |
20080206152 | In Vivo Expression Profiling - The present invention relates to in vivo expression profiling using a plurality of specific targeting moieties each labelled with a different compound which allows to identify simultaneously the binding of each targeting moiety to a target. | 2008-08-28 |
20080206153 | Copolymers for Cosmetic Agents, Produced in the Presence of Polyfunctional Chain Transfer Agents - The present invention relates to cosmetic and pharmaceutical compositions which comprise a copolymer with anionogenic and/or anionic groups which is obtainable by free-radical polymerization of a monomer mixture in the presence of a polyfunctional regulator with at least three functional regulating groups. The invention further relates to a method of producing such a copolymer and to the copolymers obtainable by this method. | 2008-08-28 |
20080206154 | Single-Stranded Antimicrobial Oligonucleotides and Uses Thereof - The current invention is directed to oligonucleotide sequences isolated from a sequence designated rbl-1 [SEQ ID NO. 19] that either kill or inhibit growth, or prevent the production of endogenously expressed toxin, of microorganisms. These ssDNA sequences, identified through use of a screening method, appear to act as modulators of essential growth functions which may act at the level of triplex formation, antisense inhibition, or as aptamers that alter gene function. The sequences, referred to as minimum functional regions, or MFRs, are useful inter alia as therapeutic agents for treatment of sepsis and other pathologies caused by microorganisms such as sepsis and/or in which microorganisms are contributory agents. | 2008-08-28 |
20080206155 | STABLE NON-ALCOHOLIC FOAMABLE PHARMACEUTICAL EMULSION COMPOSITIONS WITH AN UNCTUOUS EMOLLIENT AND THEIR USES - A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.5% to about 15% by weight; water; an effective amount of an active pharmaceutical agent having a degree of solubility in the emulsion composition; and at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the unctuous emollient comprises a petrolatum alone or in combination with other unctuous agents; wherein the multi active agent is selected from the group consisting of (a) two or more complex emulgators wherein there is a difference of about 4 or more units between the HLB values of two of the emulgators or there is a significant difference in the chemical nature or structure of two of the emulgators; (b) a surfactant and a foam adjuvant or co surfactant, wherein the surfactant has a HLB close to the required HLB of the oil phase; (c) a surfactant and a liquid wax, wherein the surfactant has a HLB close to the required HLB of the oil phase; (d) a surfactant and a polymeric agent other than starch or a modified starch ester, wherein the surfactant has a HLB close to the required HLB of the oil phase; (e) a polymeric agent and a foam adjuvant or co surfactant, which can cooperate to stabilize the emulsion; (f) a single surfactant without a long polymeric side chain that is composed of a mixture of esters having a HLB close to the required HLB of the oil phase; combinations of any of the above, and wherein the composition is substantially flowable is stored in an pressurized container and upon release expands to form a breakable foam. | 2008-08-28 |
20080206156 | Continuous spray scalp therapy and dispensing systems for same - The present invention relates to continuous spray medications involving the scalp, such as minoxidil, finesteride, copper peptides, DHT inhibitors and androgen receptor blockers, for example, in an amount sufficient to stimulate or maintain hair growth. The scalp medication is disposed within a pharmacologically acceptable carrier solution. In further embodiments, the spray scalp medication is dispensed within a product bag containing the medication in liquid form. The product bag is disposed within a container and includes a sheet of gas impervious material having a barrier layer therein. A gaseous propellant is also disposed within the container and is substantially separated from the medication. The valve assembly is selectively operated to produce a fine mist of said medication which is non-chilling, continuous and even. | 2008-08-28 |
20080206157 | CEREBRAL PROTECTION WITH A XENON-CONTAINING GAS - Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature). | 2008-08-28 |
20080206158 | Benzoic Acid Ester Compounds, Compositions, Uses and Methods Related Thereto - Benzoic acid ester compounds of formula (I): | 2008-08-28 |
20080206159 | COMPOSITIONS WITH MODULATING AGENTS - The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam. | 2008-08-28 |
20080206160 | Short bio-active peptides for cellular and immunological modulation - Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed. | 2008-08-28 |
20080206161 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF - The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition. | 2008-08-28 |
20080206162 | Composition and Methods for Treating Alzheimer's Disease and Other Amyloidoses - A method of treating an amyloid disease in a patient or inhibiting the formation, deposition, accumulation, or persistence, of amyloid fibrils, amylin fibrils, or islet amyloid fibrils, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in type II diabetes in a mammalian subject. In the method a therapeutically effective amount of plant matter form the genus | 2008-08-28 |
20080206163 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one - Compounds of general formula (I) wherein each of R | 2008-08-28 |
20080206164 | Cosmetic composition comprising at least one cationic polyurethane and at least one vinyl pyrrolidone homo- or copolymer, and method of styling therewith - The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable aqueous medium:
| 2008-08-28 |
20080206165 | Single-use personal care products and kits comprising same - Single-use personal care products and kits comprising the same are disclosed. At least some of the single-use products include a pre-measured amount of a shaving composition. | 2008-08-28 |
20080206166 | Oral soap composition for cleaning teeth - Provided herein is an oral soap composition comprising an orally-acceptable soap base effective to clean teeth that includes one or more natural oils, a saponifying agent and distilled water. The oral soap composition may be liquid or solid. Also provided are oral soap compositions comprising an essential oil for flavoring. | 2008-08-28 |
20080206167 | Oral soap composition for cleaning teeth - Provided herein is an oral soap composition comprising an orally-acceptable soap base gel effective to clean teeth that includes one or more natural oils saponified by a saponifying agent, e.g., potassium hydroxide or sodium hydroxide in distilled water. The oral soap composition may be liquid or solid. Also provided are oral soap compositions comprising an essential oil or natural or artificial flavorant for flavoring. Further provided are liquid oral soap compositions that include honey and/or an essential oil. | 2008-08-28 |
20080206168 | Personal Care Compositions - The deposition of a benefit agent on a substrate after treatment of the substrate with a personal care composition which has a viscosity of at least 50 mPa·s at 25° C. and comprises the benefit agent and a low molecular weight surfactant is improved when a water-soluble polymer is used as a substitute for at least a portion of the low molecular weight surfactant. The headspace concentration of a fragrance provided by such personal care composition is also increased. | 2008-08-28 |
20080206169 | Personal care composition - Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier. | 2008-08-28 |
20080206170 | Creatine compositions for skin treatment - The present invention relates to the use of creatine compounds, such as, for example, creatine monohydrate, creatine pyruvate and creatine ascorbate, for the treatment of skin. | 2008-08-28 |
20080206171 | CONDITIONED MEDIUM AND USES THEREOF - The invention relates to compositions containing an agent that has an irritant side effect and a conditioned cell culture medium and/or of an extract thereof, for use, e.g., in the treatment of signs of inflammation and/or of immune disorders, the medium being obtainable by contact with at least one culture of digestive tract cells and at least one probiotic microorganisms. Methods of use. | 2008-08-28 |
20080206172 | CLEAR SUNSCREEN GELS AND METHODS OF USE THEREOF - The present invention relates to an alcohol-free transparent sunscreen composition containing at least one chemical ultra-violet (UV) light absorber, at least one solvent and at least one diphenyl silicone elastomer gellant. Preferably, the solvent is selected from the group consisting of dimethicone, dicaprylyl carbonate, lauryl lactate, neopentyl glycol diheptanoate, glycerin, and combinations thereof, and the diphenyl silicone elastomer gellant contains diphenylsiloxy phenyl trimethicone. Such a transparent sunscreen composition can be used to form a stable and aesthetically appeal clear gel for protecting skin against harmful effects of UV radiation. | 2008-08-28 |
20080206173 | NAIL COMPOSITIONS IN POWDERED FORM - A process for making up nails involving the steps of: (a) providing a first composition, in powder form, containing: (i) at least one colorant, in powder form; (ii) optionally, at least one film-forming polymer, in powder form; and (iii) optionally, at least one plasticizer; (b) providing a second composition containing: (iv) at least one solvent; (v) at least one film-forming polymer chosen from nitrocellulose, cellulose acetate butyrate, and mixtures thereof; and (vi) at least one plasticizer; (c) depositing the first composition onto a nail surface; and (d) applying the second composition over-top of the first composition. | 2008-08-28 |
20080206174 | LUSTROUS AND SCRATCH-RESISTANT NAIL VARNISH THROUGH ADDITION OF SILANES - A nail varnish additive contains a) at least one silane of the general formula | 2008-08-28 |
20080206175 | Composition for Skin Whitening and Wrinkle Improvement Comprising Vaccinium Uliginosum Extract and Method for Preparation Thereof - The present invention relates to a composition for the skin whitening and wrinkle improvement, comprising an extract of | 2008-08-28 |
20080206176 | Personal Care Composition Comprising Aminosilicone and Naturally Derived Cationic Polymers - The present invention is directed to a personal care composition comprising:
| 2008-08-28 |
20080206177 | Cosmetic composition comprising at least one cationic polyurethane and at least one polyethylene glycol ester, to be applied during hair dressing - The present disclosure relates to a cosmetic composition comprising in a cosmetically acceptable medium:
| 2008-08-28 |
20080206178 | Viscoelastic cosmetic composition for styling and conditioning of human hair - The sensory attributes of cosmetic compositions are very important to form positive consumer's perception of the product. The sensory attributes can vary significantly depending on the formulation employed. In the present invention, a particularly beneficial balance of attributes was attained to create a usable viscoelastric composition that can be poured as a liquid matter, handled as a solid matter and applied to hair as a styling and conditioning product. This composition comprises a unique blend of ingredients in an aqueous medium which achieves the desired results. | 2008-08-28 |
20080206179 | Personal Care Compositions Containing Cationic Synthetic Copolymer and a Detersive Surfactant - A personal care composition comprising:
| 2008-08-28 |
20080206180 | Hair and/or scalp Care Compositions Incorporating Amino-Oxo-Indole-Ylidene Compounds - A hair and/or scalp treatment composition comprising an amino-oxo-indole-ylidene compound of general formula (I): (I) formula should be here in which: R1, R2, R3 and R4 are each, independently, hydrogen or a monovalent organic group selected from alkyl, alkenyl, alkynyl, aryl, alkylenearyl, cycloalkyl, cycloalkenyl, and heterocyclyl. | 2008-08-28 |
20080206181 | Hair treatment compositions containing sophora alkaloids - The invention provides a hair treatment composition comprising one or more alkaloids derivable from plants of the | 2008-08-28 |
20080206182 | Conjugates of a Polymer and a Protein Linked by an Oxime Group - The present invention relates to polymers functionalized by an aminooxy group or a derivative thereof, conjugates, wherein the functionalized polymers are covalently coupled with a protein by an oxime linking group, a process for preparing the functionalized polymers, a process for preparing the conjugates, functionalize polymers as obtainable by the process of the present invention, conjugates as obtainable by the process of the present invention, and pharmaceutical compositions comprising at least one conjugate of the present invention and the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body. | 2008-08-28 |
20080206183 | Method of Preparing Grafted Polylysine Dendrimers - The use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerization of the aforementioned monomers of active a-amino acids in an aqueous solvent and can be resolubilized in the solvent. | 2008-08-28 |
20080206184 | Chemically Modified Protein Compositions and Methods - The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof. | 2008-08-28 |
20080206185 | Personal Care Composition Comprising a Silicone Elastomer - The present invention is directed to a personal care composition comprising: | 2008-08-28 |
20080206186 | Pro-Angiogenic Polymer Scaffolds - A pro-angiogenic porous polymer scaffold is disclosed. The polymer has at least 20 mol-% monomeric subunits containing acidic functional groups, and has a porosity of at least 40%. The pores in the scaffold are interconnected. A method of making such a scaffold using a novel adaptation to the traditional solvent casting/particulate leaching technique is also disclosed. The scaffold may be used for tissue regeneration. | 2008-08-28 |
20080206187 | METHOD FOR TREATING A NEOPLASTIC DISORDER - A method for treating a neoplastic disorder in a subject includes administering to the neoplastic cells a neoplastic cell-sensitizing composition including a poly(ethylene oxide)-poly(propylene oxide) copolymer. The poly(ethylene oxide)-poly(propylene oxide) copolymer can sensitize the neoplastic cells to hyperthermia. Energy can be applied to the neoplastic cells to heat and ablate the cells. | 2008-08-28 |
20080206188 | Therapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound - The present invention provides a system for delivering a wide range of chemical and biological therapeutics, including protein therapeutics, via transepithelial routes. The system comprises a high molecular weight polyethylene glycol-like (HMW PEG-like) compound for use with a therapeutic compound. Optionally, the system comprises a composition containing one or more HMW PEGlike compounds and one or more therapeutics, supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Administered alone, the HMW PEG-like compounds also provide therapeutic benefits. Also provided are methods for preventing or treating epithelial diseases, disorders, or conditions, such as an epithelium at risk of developing gut-derived sepsis attributable to an intestinal pathogen, as well as methods for monitoring the administration of HMW PEG-like compounds. | 2008-08-28 |
20080206189 | METHOD OF TREATING CANCER BY ADMINISTERING CONJUGATES COMPRISING HUMAN IL-18 AND SUBSTITUTION MUTANTS THEREOF - Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines. | 2008-08-28 |
20080206190 | Glycosylated IL-7, Preparation And Uses - The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects. | 2008-08-28 |
20080206191 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2008-08-28 |
20080206192 | Combination Therapy - The invention provides combination treatments with IL-21, analogues and derivatives thereof. | 2008-08-28 |
20080206193 | Method for treatment and management of thyroid cancer using immunomodulatory compounds - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-08-28 |
20080206194 | Method for the treatment of breast cancer - A method for inducing ERα expression in cancer cells in a subject affected with cancer cells which are ERα (−) is disclosed. The method involves administering to the subject an effective amount of a PPARγ antagonist alone or in combination with anti-estrogen therapy. | 2008-08-28 |
20080206195 | Compositions and Methods for Treating Disorders Associated with Abnormal Phosphate Metabolism - The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets. The present invention further provides methods and kits for diagnosing familial tumoral calcinosis as well as for identifying agents suitable for treating disorders associated with abnormal phosphate metabolism. | 2008-08-28 |
20080206196 | Differentiation of cord blood into neural like cells, and method to treat neurological condition patients - The invention discloses a method of expansion and differentiation umbilical cord blood cells into neural-like cells in clinic grade, the cell preparation and herein the method for treating neurological condition in human. | 2008-08-28 |
20080206197 | Metabolically activated recombinant viral vectors and methods for their preparation and use - Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence. | 2008-08-28 |
20080206198 | Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders - Agents and methods to alter epithelial sodium channel (ENaC) activity. | 2008-08-28 |
20080206199 | Chimeric Herpes Viruses and Uses Thereof - Disclosed herein are chimeric herpesviruses as well as methods of making and using such chimeric herpesviruses. The chimeric viruses comprise two nucleic acid sequences, one from a herpesvirus and one from a different virus. The herpesvirus nucleic acid sequence is a modified protein kinase R (PKR) evasion gene. The second viral nucleic acid sequence inhibits PKR-mediate protein shutoff in tumor cells, but is not neurovirulent. Thus, the chimeric virus has reduced neurovirulence as compared to the wild-type herpesvirus but remains replication competent. | 2008-08-28 |
20080206200 | Selected endothelial progenitor cells and methods for use - The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α | 2008-08-28 |
20080206201 | Recombinant Newcastle Disease Virus - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof. | 2008-08-28 |
20080206202 | METHODS FOR APPLICATION OF ENDOGENOUS OR EXOGENOUS STEM/PROGENITOR OR THEIR PROGENY FOR TREATMENT OF DISEASE - We propose here that endogenous stem/progenitor cells of the developing or adult nervous system be genetically modified in situ, to express therapeutically advantageous gene products. Furthermore, we propose here that endogenous or other exogenous stem cells or their progeny be genetically modified when appropriate to express advantageous gene products (and/or modified through culture techniques), and that, if exogenously derived, they be transplanted into the ventricular system of the patient nervous system, the germinal zone of the ventricular system, into postmitotic regions of the CNS or other organs. | 2008-08-28 |
20080206203 | Method for Inhibiting Tumor Metastasis - A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, thereby preventing tumor cell extravasation. | 2008-08-28 |
20080206204 | Human parthenogenetic stem cells - The invention provides a method for establishing pluripotent cell lines from human parthenotes, the uses of said cell lines for producing differentiated cells or tissues and for therapeutic applications especially in regenerative medicine. | 2008-08-28 |
20080206205 | Cd34(+) Cells And Their Methods Of Use | 2008-08-28 |
20080206206 | BONE MARROW-DERIVED NEURONAL CELLS - Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease. | 2008-08-28 |
20080206207 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 2008-08-28 |
20080206208 | EXTRAMEDULLARY ADIPOSE TISSUE CELLS AND USE THEREOF FOR REGENERATING HEMATOPOIETIC AND MUSCULAR TISSUES - The invention concerns cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue, methods for preparing them and their use in regeneration of hematopoietic lines and cardiac and skeletal muscular tissues, in particular for treating genetic or acquired hemopathies, myopathies and cardiomypathies. | 2008-08-28 |
20080206209 | MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS - One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells. | 2008-08-28 |
20080206210 | Drugs for the Prevention or Treatment of Immunodeficiencies, Autoimmune Diseases or for the Induction of Immune Tolerance - The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases. | 2008-08-28 |
20080206211 | COMPOSITION CONTAINING A CELL CULTURE MEDIUM - Composition containing a conditioned cell culture medium or an extract thereof, said medium being able to be obtained by contact with at least one culture of digestive tract cells and at least one probiotic microorganism. It also relates to the use of conditioned culture medium for improving skin homeostasis, etc. | 2008-08-28 |
20080206212 | METHOD FOR THE UTILIZATION OF AND PRODUCT CONTAINING INACTIVATED PROBIOTIC - A novel method and product utilizing or containing one or more inactivated probiotics. | 2008-08-28 |
20080206213 | METHOD FOR REDUCING OR PREVENTING SYSTEMIC INFLAMMATION - The present invention is directed to a novel method for treating or preventing systemic inflammation in a subject. The method administering to the subject a therapeutically effective amount of inactivated LGG. | 2008-08-28 |
20080206214 | Inhibition of pathogens by probiotic bacteria - Compositions containing a lactic acid-producing bacterial strain, e.g., | 2008-08-28 |
20080206215 | APPARATUS AND METHOD FOR TREATMENT OF MICROORGANISMS DURING PROPAGATION, CONDITIONING AND FERMENTATION - A method of reducing undesirable microorganism concentration, promoting desirable microorganism propagation/conditioning, and increasing desirable microorganism efficiency in an aqueous fluid stream includes (a) introducing a quantity of fermentable carbohydrate or cellulose to an aqueous fluid stream, (b) introducing a quantity of desirable microorganism to the aqueous fluid stream, (c) generating ClO | 2008-08-28 |